Bellevue Group AG Boosts Stock Position in AbbVie Inc. $ABBV

Bellevue Group AG boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 18.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 159,661 shares of the company’s stock after buying an additional 24,421 shares during the period. Bellevue Group AG’s holdings in AbbVie were worth $29,636,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ABBV. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie in the 2nd quarter worth about $25,000. TD Capital Management LLC increased its stake in AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after purchasing an additional 58 shares in the last quarter. Spurstone Advisory Services LLC purchased a new position in AbbVie in the second quarter worth about $28,000. Financial Gravity Companies Inc. bought a new position in shares of AbbVie in the second quarter worth approximately $36,000. Finally, Bear Mountain Capital Inc. grew its holdings in shares of AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after buying an additional 173 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ABBV shares. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. UBS Group boosted their price target on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 price objective (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. BMO Capital Markets lifted their price objective on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Finally, Guggenheim upped their target price on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $244.55.

AbbVie Stock Down 0.2%

AbbVie stock opened at $223.45 on Friday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The stock has a fifty day moving average of $227.25 and a 200 day moving average of $209.59. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The stock has a market cap of $394.92 billion, a PE ratio of 169.28, a price-to-earnings-growth ratio of 1.21 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the company posted $3.00 EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.1%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.